AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06759844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: A mobile health application that facilitates self-management of chronic conditions through daily education, personalized goal setting, and lifestyle monitoring. The intervention aims to improve participants' health behaviors and clinical outcomes by promoting active engagement with their health.
Study NCT00995397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% cream
Description: Small amount applied over the lesion twice a day for 7 days.
Study NCT06778044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReDirection 1.0
Description: A free, anonymous, online, self-guided cognitive behavioral therapy (CBT) intervention. Consists of 6 modules.
Study NCT06778044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReDirection 2.0
Description: A free, anonymous, online, self-guided, cognitive behavioural therapy (CBT) intervention. Consists of 5 modules and the option for asynchronous messaging with a ReDirection specialist.
Study NCT06778044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Participants in the waitlist control will wait six weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing sexual urges and behaviour.
Study NCT06778213 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NovoHelisen Depot
Description: allergen immunotherapy treatment for 12 months with house dust mite allergen preparation
Study NCT06778213 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NovoHelisen Depot
Description: allergen immunotherapy treatment for 12 months with house dust mite allergen preparation
Study NCT06778421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Description: Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents
Study NCT06778421 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular injection
Description: Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents
Study NCT06778421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (Botox®) Injections
Description: Injection of 64 units of active drug at a ratio of 4 units to 0.1 mL of sterile, preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only~- Abbvie/Allergan drug.
Study NCT06778421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Placebo injection of the same volume of preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only.
Study NCT05825430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pecs block
Description: Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
Study NCT05825430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided pecs block
Description: Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
Study NCT05825430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anaesthetic technique only
Description: All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
Study NCT06777316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT4859
Description: CGT4859 is a selective FGFR2/3 inhibitor
Study NCT05738161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
Study NCT06765317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
Study NCT06765317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: 1.8 mg/kg iv C1D1 onwards, every 3 weeks
Study NCT06765317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 iv D1
Study NCT06765317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 400 mg/m2 iv D1
Study NCT05738161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
Study NCT05738161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
Study NCT06765317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 iv D1
Study NCT06765317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab:
Description: 1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
Study NCT05989126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept 8 mg PFS
Description: Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
Study NCT05087784 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps
Description: Patient-centered, technology-supported integrated survivorship- and care management
Study NCT05205746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
Study NCT05205746 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
Study NCT06462807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARC
Description: ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.
Study NCT05502328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
Study NCT06252402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/HIV-CAR T Cells
Description: Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.
Study NCT06778655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5% propolis gel
Description: 5% propolis gel (prepared according to Joshy et al. 2018) Joshy A, Doggalli N, Patil K, Kulkarni PK. To Evaluate the Efficacy of Topical Propolis in the Management of Symptomatic Oral Lichen Planus: A Randomized Controlled Trial. Contemp Clin Dent. 2018 Jan-Mar;9(1):65-71.
Study NCT06778655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: placebo mucoadhesive gel having the same flavor, consistency, and color as the propolis.
Study NCT06056570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dontinurad
Description: dotinurad alone
Study NCT06056570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dotinurad + allopurinol
Description: dotinurad + allopurinol 300mg
Study NCT06056570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: allopurinol 300 mg alone
Study NCT05652504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 Pf sporozoites (PfSPZ) produced by Sanaria Inc. PfSPZ Vaccine is manufactured in compliance with Good Manufacturing Practice (GMP) regulations (21 Code of Federal Regulations \[CFR\] 21), that is described in detail in Investigational New Drug (IND) 13969. Manufacture of PfSPZ Vaccine is performed in Sanaria s Clinical Manufacturing Facility (CMF) in Rockville, Maryland, USA.
Study NCT05652504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PfSPZ Diluent
Description: The diluent for PfSPZ Vaccine is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA) and is termed PfSPZ Diluent (or Diluent). The PfSPZ Diluent was manufactured in compliance with GMP by Sanaria, Inc. (9800 Medical Center Dr., Rockville, MD, USA), or Sanaria s contractor Emergent Biosolutions (https://www.emergentcdmo.com/). Each lot of PfSPZ Diluent is issued a Certificate of Analysis (CoA) and is also placed on a stability program. HSA used in PfSPZ Diluent is a licensed product which is approved for parenteral, IV administration to humans and is purchased by Sanaria, Inc. from CSL Behring, Bern, Switzerland.
Study NCT05652504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
Study NCT05502328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
Study NCT06071091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial stenting
Description: In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication.
Study NCT06071091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical care, without additional endovascular procedures
Description: The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)
Study NCT04194424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight loss program
Description: Diet and behavioral therapy,and supervised exercise sessions
Study NCT04194424 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: General lifestyle tips
Study NCT04194424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Hcl 850Mg Tab
Description: 1 tablet, twice daily
Study NCT06236542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextGen automated tracheostomy suctioning device
Description: Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
Study NCT06236542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextGen mixed-reality tracheostomy tube change system
Description: Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
Study NCT06236542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextGen Tracheostomy Toolkit
Description: Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
Study NCT06485973 — intervention group
Intervention type: OTHER
Intervention: Modified Dental Anxiety Scale (MDAS)
Description: The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
Study NCT05191888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan and Amoxicillin
Description: 14-day vonoprazan high-dose two-in-one therapy
Study NCT05191888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan, Amoxicillin and Clarithromycin
Description: 14-day vonoprazan triple therapy
Study NCT05191888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole
Description: 14th Rabeprazole reverse mixed therapy
Study NCT04194424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hcl 850Mg Tab
Description: 1 tablet, twice daily
Study NCT06013722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Na PET Scan
Description: For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
Study NCT05078229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS
Description: There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
Study NCT05078229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: 20mg hydrocortisone, single oral dose
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine Hydrochloride
Description: 54mg yohimbine hcl, single oral dose
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine Hydrochloride
Description: 54mg yohimbine hcl, single oral dose
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch Placebo 20mg
Description: 20mg cornstarch placebo, single oral dose
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cornstarch Placebo 20mg
Description: 20mg cornstarch placebo, single oral dose
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cornstarch Placebo 54mg
Description: 54mg cornstarch placebo, single oral dose
Study NCT06430580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch Placebo 54mg
Description: 54mg cornstarch placebo, single oral dose
Study NCT06019169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga arm
Description: Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
Study NCT06019169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: storytelling activities
Description: Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
Study NCT05090137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diuretics
Description: As per group descriptions
Study NCT04829708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Surveillance
Description: Receive MRI surveillance
Study NCT04829708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI Surveillance
Description: Receive MRI surveillance
Study NCT04829708 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Cranial Irradiation
Description: Receive PCI
Study NCT05778084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
Study NCT06581731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam combined with remifentanil
Description: Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
Study NCT06581731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine combined with remifentanil
Description: Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
Study NCT05858632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab treatment for \~ 9 months
Study NCT06127264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
Study NCT06166160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk fill flowable composite SDR Dentsply sirona
Description: caries removal in class II cavities of primary molars and application of experminted restorations
Study NCT06166160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill flowable composite SDR Dentsply sirona
Description: caries removal in class II cavities of primary molars and application of experminted restorations
Study NCT06102759 — intervention group
Intervention type: DRUG
Intervention: Adebrelimab，Fruquintinib
Description: Adebrelimab，Fruquintinib combined with chemotherapy
Study NCT04869137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: 20mg of Lenvatinib will be taken orally once daily
Study NCT04869137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
Study NCT05021562 — intervention group
Intervention type: DRUG
Intervention: Niraparib
Description: Niraparib capsules